The ENRICH trial showed that the combination of ibrutinib and rituximab significantly improved progression-free survival compared to standard immunochemotherapy in older patients with mantle-cell lymphoma. Ibrutinib-rituximab demonstrated a unique efficacy and safety profile, suggesting it should be considered a new standard of care option.
Study
|
Randomized, open-label, phase 2/3 trial [ENRICH] |
| Patients 60 years and older with previously untreated Stage II-IV mantle-cell lymphoma |
| Ibrutinib+Rituximab (n=199) vs Immunochemotherapy (R-CHOP n=53; Rituximab-Bendamustine n=145)
|
Efficacy
|
ORR: 86% vs 89% vs 84% (Ibrutinib+Rituximab; R-CHOP; Rituximab-Bendamustine) |
| CR: 54% vs 47% vs 55% |
| mPFS: 65.3 mos vs 42.4 mos (Ibrutinib-Rituximab vs. Immunochemotherapy, HR 0.69 [0.52-0.90]) |
| 5-year PFS: 52% vs 19% vs 47%
|
Safety
|
Grade >=3 AEs: 67% vs 71% vs 69% Neutropenia: 9% vs 21% vs 19% Hypertension: 11% vs 4% vs 1% Atrial fibrillation: 7% vs 1% vs 1% Infection: 12% vs 23% vs 11% Treatment discontinuations: 21% due to disease progression
|
Lancet Oncol. Published online 2025.
http://doi.org/10.1016/S0140-6736(25)01432-1
Reviewed by Ulas D. Bayraktar, MD on Oct 23, 2025
